150 related articles for article (PubMed ID: 29894469)
1. OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.
Kers JA; DeFusco AW; Park JH; Xu J; Pulse ME; Weiss WJ; Handfield M
PLoS One; 2018; 13(6):e0197467. PubMed ID: 29894469
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological, Toxicological, and Dose Range Assessment of OG716, a Novel Lantibiotic for the Treatment of
Pulse ME; Weiss WJ; Kers JA; DeFusco AW; Park JH; Handfield M
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670434
[TBL] [Abstract][Full Text] [Related]
3. Mutacin 1140 Lantibiotic Variants Are Efficacious Against
Kers JA; Sharp RE; Defusco AW; Park JH; Xu J; Pulse ME; Weiss WJ; Handfield M
Front Microbiol; 2018; 9():415. PubMed ID: 29615987
[TBL] [Abstract][Full Text] [Related]
4. Current developments in lantibiotic discovery for treating Clostridium difficile infection.
Sandiford SK
Expert Opin Drug Discov; 2019 Jan; 14(1):71-79. PubMed ID: 30479173
[TBL] [Abstract][Full Text] [Related]
5. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
[TBL] [Abstract][Full Text] [Related]
6. Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile.
Mathur T; Kumar M; Barman TK; Kumar GR; Kalia V; Singhal S; Raj VS; Upadhyay DJ; Das B; Bhatnagar PK
J Antimicrob Chemother; 2011 May; 66(5):1087-95. PubMed ID: 21393140
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
Crowther GS; Baines SD; Todhunter SL; Freeman J; Chilton CH; Wilcox MH
J Antimicrob Chemother; 2013 Jan; 68(1):168-76. PubMed ID: 22966180
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic strategies for Clostridium difficile infections.
Ünal CM; Steinert M
Expert Opin Ther Targets; 2016; 20(3):269-85. PubMed ID: 26565670
[TBL] [Abstract][Full Text] [Related]
9. Carboxyl Analogue of Mutacin 1140, a Scaffold for Lead Antibacterial Discovery.
Escano J; Ravichandran A; Salamat B; Smith L
Appl Environ Microbiol; 2017 Jul; 83(14):. PubMed ID: 28500042
[TBL] [Abstract][Full Text] [Related]
10. Infection of hamsters with historical and epidemic BI types of Clostridium difficile.
Razaq N; Sambol S; Nagaro K; Zukowski W; Cheknis A; Johnson S; Gerding DN
J Infect Dis; 2007 Dec; 196(12):1813-9. PubMed ID: 18190262
[TBL] [Abstract][Full Text] [Related]
11. Refinement of the hamster model of Clostridium difficile disease.
Douce G; Goulding D
Methods Mol Biol; 2010; 646():215-27. PubMed ID: 20597012
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.
Cherian PT; Wu X; Yang L; Scarborough JS; Singh AP; Alam ZA; Lee RE; Hurdle JG
J Antimicrob Chemother; 2015 Nov; 70(11):3061-9. PubMed ID: 26286574
[TBL] [Abstract][Full Text] [Related]
13. Nonantimicrobial drug targets for Clostridium difficile infections.
Darkoh C; Deaton M; DuPont HL
Future Microbiol; 2017 Sep; 12(11):975-985. PubMed ID: 28759258
[TBL] [Abstract][Full Text] [Related]
14. Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections.
Gil F; Paredes-Sabja D
Future Microbiol; 2016 Sep; 11():1179-89. PubMed ID: 27546386
[TBL] [Abstract][Full Text] [Related]
15. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection.
Gómez S; Chaves F; Orellana MA
Anaerobe; 2017 Dec; 48():147-151. PubMed ID: 28830842
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial and Solubility Optimization of Thiomuracin A.
LaMarche MJ; Leeds JA; Brewer J; Dean K; Ding J; Dzink-Fox J; Gamber G; Jain A; Kerrigan R; Krastel P; Lee K; Lombardo F; McKenney D; Neckermann G; Osborne C; Palestrant D; Patane MA; Rann EM; Robinson Z; Schmitt E; Stams T; Tiamfook S; Yu D; Whitehead L
J Med Chem; 2016 Jul; 59(14):6920-8. PubMed ID: 27355833
[TBL] [Abstract][Full Text] [Related]
17. The potential for emerging therapeutic options for Clostridium difficile infection.
Mathur H; Rea MC; Cotter PD; Ross RP; Hill C
Gut Microbes; 2014; 5(6):696-710. PubMed ID: 25564777
[TBL] [Abstract][Full Text] [Related]
18. A new strategy for the prevention of Clostridium difficile infection.
Howerton A; Patra M; Abel-Santos E
J Infect Dis; 2013 May; 207(10):1498-504. PubMed ID: 23420906
[TBL] [Abstract][Full Text] [Related]
19. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.
Freeman J; Marquis M; Crowther GS; Todhunter SL; Fawley WN; Chilton CH; Moeck G; Lehoux D; Wilcox MH
J Antimicrob Chemother; 2012 Dec; 67(12):2919-26. PubMed ID: 22899803
[TBL] [Abstract][Full Text] [Related]
20.
Banawas SS
Biomed Res Int; 2018; 2018():8414257. PubMed ID: 29682562
[No Abstract] [Full Text] [Related]
[Next] [New Search]
